A measured research overview of the GHRP-6 peptide: its ghrelin-receptor mechanism, growth-hormone and appetite effects, CD36 cytoprotective research, and how it compares to GHRP-2 and ipamorelin.
GHRP-6 is the compound that started a field. Synthesized in the early 1980s by endocrinologist Cyril Y. Bowers at Tulane University from modified met-enkephalin analogs, it was the first synthetic peptide shown to reliably trigger growth hormone (GH) release in the laboratory. Every later growth hormone secretagogue in this class — GHRP-2, hexarelin, and ipamorelin — descends from it. This overview covers what the published research actually establishes about GHRP-6, where the data are firm, and where they remain preliminary.
GHRP-6 is a synthetic hexapeptide — six amino acids, sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. The D-amino acid substitutions make it resistant to rapid enzymatic breakdown, which is why a short synthetic peptide can act as a functional secretagogue at all. It is a secretagogue: it does not supply growth hormone, it prompts the pituitary to release the GH it already stores.
Its most consequential legacy is indirect. GHRP-6 was designed and studied years before anyone knew what natural molecule it was imitating. It was the pharmacological probe that led Kojima and colleagues, in 1999, to identify ghrelin — the stomach-derived "hunger hormone" — as the endogenous ligand for the receptor GHRP-6 had been hitting all along.
GHRP-6 is an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), now better known as the ghrelin receptor. Activating GHS-R1a on pituitary somatotrophs stimulates GH release in a pulsatile pattern that broadly resembles the body's own rhythm, rather than the flat, continuous exposure of administered recombinant GH.
Two features of the mechanism matter for interpreting the research:
A second, less-appreciated line of research points to a non-GH mechanism. GHRP-6 also binds the scavenger receptor CD36, expressed in myocardium and other tissues. Work led by Berlanga-Acosta's group at Cuba's Center for Genetic Engineering and Biotechnology attributes much of GHRP-6's cytoprotective and cardioprotective activity to this CD36 route, operating independently of GH release.
Growth hormone release. This is the best-established effect. Human neuroendocrine studies — including Arvat and colleagues' 2001 comparison of GHRP-6, hexarelin, and ghrelin in the Journal of Clinical Endocrinology & Metabolism — consistently document robust, dose-dependent GH secretion after GHRP-6 administration.
Appetite. GHRP-6 produces the strongest appetite stimulation of the synthetic GHRPs, markedly more than GHRP-2 and far more than ipamorelin. In research contexts this is a defining characteristic, not a side note.
Off-target hormones. Because GHS-R1a activation is not confined to GH pathways, GHRP-6 co-stimulates ACTH/cortisol and prolactin. Reported elevations are generally modest and transient, and are dose- and route-dependent — intravenous boluses provoke more than lower-concentration or intranasal delivery.
Tissue protection. The cardioprotective and cytoprotective literature is the most intriguing and the least mature. Preclinical models — porcine myocardial infarction, and a 2024 rodent model of doxorubicin cardiotoxicity — report reduced myocardial necrosis and activation of pro-survival pathways. These are animal findings from a small number of groups; they are hypothesis-generating, not established outcomes.
GHRP-6 is the least selective member of its family. That is the whole story of the class's evolution: each successor traded some of GHRP-6's breadth for cleaner GH release.
| Compound | Selectivity | Appetite effect | Off-target (cortisol/prolactin) |
|---|---|---|---|
| GHRP-6 | Lowest | Strong | Present, dose-dependent |
| GHRP-2 | Moderate | Moderate | Lower than GHRP-6 |
| Ipamorelin | Highest | Negligible | Minimal at standard doses |
For a broader map of how these fit alongside GHRH analogues like CJC-1295 and sermorelin, see the growth-hormone secretagogues category guide. For the direct successor, see the GHRP-2 research overview.
GHRP-6's GH-releasing and appetite effects are well characterised in animal and human neuroendocrine studies. Beyond that, the picture thins quickly. The cytoprotective work is preclinical and concentrated in a few laboratories; there are no large, replicated human efficacy trials for the organ-protection claims. GHRP-6 has never been an approved therapeutic. Treat the discovery-era GH data as solid and everything downstream as an open research question.
Is GHRP-6 the same as ghrelin? No. GHRP-6 is a synthetic hexapeptide that activates the same receptor (GHS-R1a) as ghrelin, the body's natural ligand. Historically, studying GHRP-6 is what led researchers to discover ghrelin in 1999.
Why does GHRP-6 cause hunger in studies? Its receptor, GHS-R1a, is heavily expressed in appetite-regulating regions of the hypothalamus. Activating it engages the same signalling ghrelin uses to promote food intake, so strong appetite stimulation is an intrinsic feature of the compound rather than an impurity effect.
How is GHRP-6 different from ipamorelin? Both are ghrelin-receptor agonists, but ipamorelin is highly selective for GH release with negligible appetite, cortisol, or prolactin effects. GHRP-6 is the least selective of the family and co-stimulates those other pathways.
Does GHRP-6 have a short half-life? Yes. It is cleared quickly — on the order of tens of minutes — which is why the research literature describes pulsatile rather than sustained GH responses.
Is the cardioprotective research established? No. Those findings come from preclinical animal and cell models, largely from a small number of research groups, and have not been confirmed in large human trials. They are promising but early-stage.